January 14, 2021

Delfi Diagnostics Announces $100 Million Series A Financing to Develop a New Class of Early Detection Liquid Biopsy for Multiple Cancers

Novel liquid biopsy technology combines machine learning and low-cost cell free DNA genome-wide fragmentation profiles NEWS PROVIDED BY Delfi Diagnostics  BALTIMORE, Jan. 12, 2021 /PRNewswire/ — Delfi Diagnostics, Inc., a pioneering developer of … Continued